Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment Leukemia (2008) To exploit the diagnostic usefulness of the recently discovered JAK2 V617F mutation, as well as the characteristic bone marrow histopathological features reported in BCR-ABL-negative chronic myeloproliferative disorders, members of the International Working Group for Myelofibrosis Research and Treatment published revised diagnostic criteria for polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis. 1 The document was endorsed by the Clinical Advisory Committee for the revision of the WHO Classification of Myeloid Neoplasms and its adoption was recommended by the WHO.
Myelofibrotic transformation is a recognized complication of PV and ET, resulting in disorders now termed as post-PV myelofibrosis and post-ET myelofibrosis according to the revised nomenclature from International Working Group for Myelofibrosis Research and Treatment group. 2 However, specific diagnostic criteria for both post-PV and post-ET myelofibrosis, have yet to be defined. During the third international meeting of the International Working Group for Myelofibrosis Research and Treatment held in Houston, TX, on 25 May 2007, a panel of expert hematologists and hematopathologists addressed these issues for both clinical entities.
From a list of candidate criteria and by group consensus, the panel selected two required criteria for the diagnoses of post-PV myelofibrosis and post-ET myelofibrosis (Table 1) . First, a verified diagnosis of pre-existing PV or ET was recommended as crucial for the diagnosis of MF transformation. Due to the Table 1 IWG-MRT recommended criteria for post-PV MF and post-ET MF
Criteria for post-polycythemia vera myelofibrosis
Required criteria: 1 Documentation of a previous diagnosis of polycythemia vera as defined by the WHO criteria 1 2 Bone marrow fibrosis grade 2-3 (on 0-3 scale) 3 or grade 3-4 (on 0-4 scale) 4,a Additional criteria (two are required):
1 Anemia b or sustained loss of requirement of either phlebotomy (in the absence of cytoreductive therapy) or cytoreductive treatment for erythrocytosis 2 A leukoerythroblastic peripheral blood picture 3 Increasing splenomegaly defined as either an increase in palpable splenomegaly of X5 cm (distance of the tip of the spleen from the left costal margin) or the appearance of a newly palpable splenomegaly 4 Development of X1 of three constitutional symptoms: 410% weight loss in 6 months, night sweats, unexplained fever (437.51C) Letters to the Editor insufficient discriminatory power of previous polycythemia vera study group (PVSG) diagnostic criteria, 1 and in particular, due to similarities of ET with prefibrotic primary myelofibrosis, the panel recommended that the previous diagnosis of PV or ET should fulfill the WHO criteria. 1 Second, careful bone marrow morphological examination is crucial in the diagnostic workup, since appearance of bone marrow fibrosis was recommended as a necessary criterion. Grade 2 or greater bone marrow fibrosis, according to the new European classification 3 or grade 3 or greater according to the standard classification, 4 was a prerequisite for the diagnosis. No other bone marrow morphological appearances were considered useful for the diagnosis of PV or ET evolving into MF. In addition to the above-mentioned two required criteria, the International Working Group for Myelofibrosis Research and Treatment recommends the presence of two additional criteria, as outlined in Table 1 , for post-PV myelofibrosis and post-ET myelofibrosis. 5 We recommend that these criteria be incorporated in the revised WHO document and be utilized in both routine clinical practice and future clinical investigations. B-cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia accounting for around 30% of all cases. Inherited predisposition to CLL is now well recognized, with epidemiological studies showing 3-to 7-fold elevations of risk in first-degree relatives of CLL cases. 1 Part of this genetic risk is likely to be explained by combinations of common, lowerpenetrance variants, making association studies an attractive means of identifying susceptibility alleles for CLL.
Recent studies have independently identified polymorphisms in the 8q24 region, including the single nucleotide polymorphism (rs6983267) to be strongly associated with risk of prostate [2] [3] [4] and colorectal cancer, 5 raising the possibility that 8q24 variants act as generic susceptibility alleles for neoplasia.
To explore the relationship between polymorphic variation at 8q24 and risk of CLL, we compared the frequency of rs6983267 genotypes in 984 cases and 4831 healthy controls. We included a high proportion of familial cases in the study as this enriches for an inherited genetic risk thereby increasing the probability of detecting an association. 6 Nine hundred and eighty-four patients with adult CLL (666 men and 318 women; mean age at diagnosis 61 years) ascertained through the Royal Marsden Hospital NHS Trust were included in the study. One hundred and thirty-three of the cases had one or more first-degree relatives affected with CLL. The diagnosis of B-cell CLL in cases was established using standard clinico-pathological and immunological criteria in accordance with current World Health Organization classification guidelines. 7 Control genotypes were based on previously published data we generated on 4831 healthy individuals (mean age 58 years; range 51-70; s.d.75). 5 All cases and controls
